Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients
Status and phase
Conditions
Treatments
Details and patient eligibility
About
This 2-arm study recruited kidney transplant patients who were receiving standard care of calcineurin inhibitors (CNIs, tacrolimus or cyclosporine), CellCept (1.0-1.5 g twice daily) and corticosteroids. They were either randomized to continue this regimen, or CNI therapy was discontinued and replaced by sirolimus therapy (in combination with CellCept and corticosteroids). The effect of these 2 regimens on efficacy, safety and kidney function was evaluated. The anticipated time on study treatment was 1-2 years, and the target sample size was 100-500 individuals.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Adult patients 18-75 years of age
- Kidney transplant 30-180 days post-transplantation
- Receipt of cyclosporine or tacrolimus, CellCept, and corticosteroids for greater than 14 days prior to study entry
- No known contraindications to sirolimus
Exclusion criteria
- Multiple organ transplant recipients or secondary kidney transplant recipients
- Corticosteroid-resistant rejection episode within 90 days prior to study entry or corticosteroid-sensitive rejection episode within 30 days prior to study entry
- More than 1 biopsy-proven episode of acute rejection prior to study entry
- Treated with sirolimus before the study
- Organ transplant or expected organ transplant, other than kidney
- History of malignancy in the last 5 years (except successfully treated localized non-melanotic skin cancer)
Trial design
Primary purpose
Allocation
Interventional model
Masking
305 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal